These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 18801827)

  • 21. The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol.
    Kleinloog D; Stevens J; Heuberger J; Spinhoven P; van Gerven J
    Psychiatry Res; 2014 Dec; 220(3):945-53. PubMed ID: 25454117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration of the electroencephalogram during bromotrifluoromethane exposure.
    Van Stee EW; Back KC; Prynn RB
    Toxicol Appl Pharmacol; 1970 May; 16(3):779-85. PubMed ID: 4987188
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharmacological properties of dihydrobenzothiazine; depressive action on interneuronic conduction in the central nervous system].
    LONGO VG
    Arch Int Pharmacodyn Ther; 1952 Feb; 89(1):55-64. PubMed ID: 14944311
    [No Abstract]   [Full Text] [Related]  

  • 24. Adolescents are more sensitive than adults to acute behavioral and cognitive effects of THC.
    Murray CH; Huang Z; Lee R; de Wit H
    Neuropsychopharmacology; 2022 Jun; 47(7):1331-1338. PubMed ID: 35110688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.
    Kayser RR; Haney M; Raskin M; Arout C; Simpson HB
    Depress Anxiety; 2020 Aug; 37(8):801-811. PubMed ID: 32383271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
    Martin-Santos R; Crippa JA; Batalla A; Bhattacharyya S; Atakan Z; Borgwardt S; Allen P; Seal M; Langohr K; Farré M; Zuardi AW; McGuire PK
    Curr Pharm Des; 2012; 18(32):4966-79. PubMed ID: 22716148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Cannabinoid Signaling in Cardiovascular Function and Ischemic Injury.
    Rorabaugh BR; Guindon J; Morgan DJ
    J Pharmacol Exp Ther; 2023 Dec; 387(3):265-276. PubMed ID: 37739804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?
    Weresa J; Pędzińska-Betiuk A; Mińczuk K; Malinowska B; Schlicker E
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional brain connectomes reflect acute and chronic cannabis use.
    Ramaekers JG; Mason NL; Toennes SW; Theunissen EL; Amico E
    Sci Rep; 2022 Feb; 12(1):2449. PubMed ID: 35165360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabis and Athletic Performance.
    Burr JF; Cheung CP; Kasper AM; Gillham SH; Close GL
    Sports Med; 2021 Sep; 51(Suppl 1):75-87. PubMed ID: 34515970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neural substrates underlying the negative impact of cannabinoid exposure during adolescence.
    Molla HM; Tseng KY
    Pharmacol Biochem Behav; 2020 Aug; 195():172965. PubMed ID: 32526217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoid
    Skolnick P; Crystal R
    J Neural Transm (Vienna); 2020 Feb; 127(2):279-286. PubMed ID: 31893308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced stress responses and addiction risk and relapse.
    Wemm SE; Sinha R
    Neurobiol Stress; 2019 Feb; 10():100148. PubMed ID: 30937354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disturbances of postural sway components in cannabis users.
    Bolbecker AR; Apthorp D; Martin AS; Tahayori B; Moravec L; Gomez KL; O'Donnell BF; Newman SD; Hetrick WP
    Drug Alcohol Depend; 2018 Sep; 190():54-61. PubMed ID: 29983392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms contributing to cognitive deficits in cannabis users.
    Mizrahi R; Watts JJ; Tseng KY
    Neuropharmacology; 2017 Sep; 124():84-88. PubMed ID: 28414051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.
    Guan Z; Klumpers LE; Oyetayo OO; Heuberger J; van Gerven JM; Stevens J
    Br J Clin Pharmacol; 2016 Apr; 81(4):713-23. PubMed ID: 26617196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profiling the subjective effects of Δ⁹-tetrahydrocannabinol using visual analogue scales.
    Kleinloog D; Roozen F; De Winter W; Freijer J; Van Gerven J
    Int J Methods Psychiatr Res; 2014 Jun; 23(2):245-56. PubMed ID: 24496889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
    Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
    Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
    Klumpers LE; Roy C; Ferron G; Turpault S; Poitiers F; Pinquier JL; van Hasselt JG; Zuurman L; Erwich FA; van Gerven JM
    Br J Clin Pharmacol; 2013 Jul; 76(1):65-77. PubMed ID: 23278647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC.
    Lile JA; Kelly TH; Hays LR
    Drug Alcohol Depend; 2012 Apr; 122(1-2):61-9. PubMed ID: 21975195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.